Tiziana Life Sciences Ltd (TLSA) stands at the forefront of biotechnology companies engaged in pioneering research related to autoimmune and inflammatory diseases, cancer, and infectious diseases. With a primary focus on developing novel treatments for a wide spectrum of diseases, it offers an impressive array of proprietary technologies.
Established in 2003, this UK-based listed company operates a dual listing structure with a presence in both the UK's AIM (Alternative Investment Market) and NASDAQ in the US. The company capitalizes on its roots in innovative biomedical research to drive its growth.
A thought leader and a significate player in the biotech industry, Tiziana Life Sciences is propelled by a vision to transform patient's lives through its potentially breakthrough therapies. The company's development involves a robust pipeline of immunotherapy biologics as well as small molecules.
Under its immunotherapy division, Tiziana Life Sciences majorly focuses on anti-Interleukin-6 receptor (anti-IL6R) monoclonal antibody. An important highlight of its drug portfolio is Foralumab, which is the only fully human anti-CD3 monoclonal antibody in clinical development in the world. It's believed to have the potential to bring transformative changes for patients suffering from a vast range of autoimmune and inflammatory diseases.
In the small molecules domain, Tiziana's lead compound is Milciclib, a resident Cyclin-Dependent Kinase inhibitor currently undergoing phase 2 clinical trials. Reported to be safe and well-tolerated in patients with advanced solid tumors such as Hepatocellular Carcinoma and Thymic Carcinoma, Milciclib is believed to have the potential to be a breakthrough in cancer treatment.
Moreover, in the face of the global COVID-19 pandemic, Tiziana Life Sciences has made significant strides in addressing this global health crisis by extensively focusing on developing a nasal spray for the direct delivery of monoclonal antibodies to combat COVID-19.
A firm believer in research and innovation, Tiziana Life Sciences Ltd champions a multidimensional research approach as its winning formula. The strategic partnership, collaborative culture, and continuous investment in research and development are its strengths. However, it's imperative to note that while biotechnology and the development of medical treatments inevitably carry a degree of inherent risk, it is companies like Tiziana Life Sciences Ltd that are leading the charge bravely to tackle some of the most pressing health challenges that confront humanity today.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Tiziana Life Sciences (NASDAQ: TLSA) has signed a Memorandum of Understanding (MOU) with Saudi research institutions to initiate a clinical trial. This trial will investigate the use of intranasal foralumab in combination with anti-CD20 therapy for relapsing-remitting multiple sclerosis (RRMS) patients who have not responded adequately to anti-CD20 treatment alone. The collaboration expands the clinical development of foralumab, specifically targeting neuroinflammation, without affecting Tiziana's ongoing program for non-active secondary progressive multiple sclerosis.
Tiziana Life Sciences (NASDAQ: TLSA) saw its stock jump over 21% after announcing a memorandum of understanding to evaluate a combination therapy for relapsing-remitting multiple sclerosis. The collaboration with King Abdullah International Medical Research Center and the Foundation for Neurologic Diseases will focus on patients who respond poorly to existing anti-CD20 therapy. The company also anticipates Phase 2 trial results for non-active secondary progressive multiple sclerosis in October.
BTIG has initiated coverage on Tiziana Life Sciences with a "Buy" rating and a price target of $7.00. This news comes alongside other recent updates from the company regarding its clinical trials for conditions such as Multiple System Atrophy and Multiple Sclerosis, highlighting its biopharmaceutical development efforts.
Tiziana Life Sciences announced a poster presentation at ALS Nexus 2026 detailing the Phase 2a BANYAN clinical trial of intranasal foralumab for Amyotrophic Lateral Sclerosis (ALS). The presentation by Dr. Pinar Uysal highlights the trial's design, preclinical data, and its focus on assessing safety, immune modulation biomarkers, and early clinical effects in ALS patients by targeting the Regulatory T Cell (Treg) pathway to reduce neuroinflammation. The BANYAN trial is part of the Healey ALS MyMatch program and is currently in its operational startup phase.
This article highlights key market movers, including Expion Energy which saw a significant stock jump after closing an initial $9 million private placement for oil and gas exploration assets. Bitmine Immersion Technologies reported $14.9 billion in crypto holdings, while MicroStrategy raised $2.01 billion through an equity offering without selling its bitcoin. Tiziana Life Sciences announced an upcoming presentation on its Phase 2a clinical trial for intranasal foralumab at ALS Nexus 2026.